Navigation Links
Combating anthrax: Results of study published this month as researchers look for a better vaccine

A new study published this month by a Saint Louis University vaccine researcher scrutinizes what in the future could be an alternative to the presently available anthrax vaccine.

This new type of anthrax vaccine produced the immune response doctors were looking for, according to peer-reviewed research published in Vaccine.

In its first human testing, the vaccine was given to 100 volunteers at four sites around the United States, said Geoffrey Gorse, M.D., a Saint Louis University researcher who was the main author of the paper.

"This type of research, five years after 9/11, continues to be very important to pursue," Gorse said. "We need a better vaccine to help protect people from anthrax infection, whether the vaccine is given before or soon after exposure to anthrax spores."

Gorse said the study was able to answer some important questions about this candidate vaccine.

"We were able to demonstrate in this study that the investigational anthrax vaccine produced an immune response that justifies further testing in larger studies," he said. "We'll be using this data to help design strategies for testing of this vaccine in the future."

Gorse indicated that the investigational vaccine, made by VaxGen Inc., demonstrated a clear relationship between the amount of vaccine administered and the subsequent immune response.

The study was designed to evaluate the safety and immunogenicity of escalating doses of the new vaccine. A total of 100 healthy adults were randomized to receive either one of four different vaccine formulations, or AVA, the anthrax vaccine currently licensed for use in the United States. All vaccinations were administered intramuscularly.


'"/>

Source:Saint Louis University


Page: 1

Related biology news :

1. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
2. Results with newer bladeless LASIK equivalent to standard microkeratome LASIK
3. Bioartificial kidney under study at MCG
4. W.M. Keck Foundation funds study of friendly microbes
5. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
6. Genome-wide mouse study yields link to human leukemia
7. Clam embryo study shows pollutant mixture adversely affects nerve cell development
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. Same mutation aided evolution in many fish species, Stanford study finds
10. Sequencing of marine bacterium will help study of cell communication
11. Genetically modified rice in China benefits farmers health, study finds
Post Your Comments:
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... an overview of sales of various drugs used in ... shown in kilograms of active ingredient; antibacterials, anaesthetics, anthelmintics ... are based on sales from wholesalers to pharmacies and ... increase in sales of antibacterials from 2002-2006, sales in ...
... an important signaling molecule in plants - as in ... herb as a model plant, researchers have found that ... in plants. In collaborative work with the research ... doctoral student at the Botany Department, University of Delhi, ...
... has contracted with Florida Tech scientists for a two-year, ... larvae and eggs (ichthyoplankton) that inhabit the St. Johns ... effort to address public concern regarding the cumulative impact ... One measure of the rivers current and ...
Cached Biology News:Nitric oxide regulates plants as well as people 2Grant to fund answers about St. Johns River 2
(Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 With only ... time special on Sartorius Biohit products . The ... mLINE pipettes, Picus Electronic Pipette Trade-in Program, and free ... and Safety officers around the world. They are ideal ... Other features include:, ,     Full volume range ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... New Findings Also Demonstrate Treatment Results in Improvements in ... Function and Health-Related Quality ... than half of patients,receiving every four week subcutaneous injections ... investigational therapy, experienced sustained,improvements in the joint and skin ...
... Cephalosporin in,Development for Complicated Skin and Skin Structure ... Oct. 27, 2008 Forest,Laboratories, Inc. (NYSE: ... I, a,globally conducted, multi-center, Phase III clinical trial, ... and Chemotherapy /,Infectious Diseases Society of America 46th ...
... 27 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ... Phase 1/2a study,demonstrating that repeat administration with ... improvements in rheumatoid arthritis,(RA) signs and symptoms ... Trubion also announced positive results following preliminary,analyses ...
Cached Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: